-
30
2020.09
Happy Mid-autumn Festival!
-
13
2020.03
TOT BIOPHARM Garners "Listing Award of Technological Company" and "Innovative Technological Research and Development Award"
-
07
2020.01
TOT BIOPHARM Included in the“Suzhou Industrial Park – 2019 Awarded Listed Enterprises” Granted Subsidy of RMB4 Million
-
10
2019.09
Leader the investigation of market license holders (MAH) pilot work
-
02
2019.09
TOT BIOPHARM won the "outstanding contribution award of science and technology research and development" in the park
-
02
2019.08
TOT BIOPHARM won the title of "2019 The Best Healthcare Investment Award"
On April 10, 2019, "the third medical and health investment summit" was hosted by haoyue capital with the theme of "breaking the wall" at intercontinental Shanghai jinjiang hotel.
-
02
2019.08
TOT BIOPHARM was awarded as "the best investment case of biomedicine of the year".
On April 22, 2019, Li lihui, convener of mainland financial industry cooperation promotion group of cross-strait entrepreneurs summit, and his delegation visited dongyao pharmaceutical.
-
02
2019.08
Li lihui visited TOT with his team of financial cooperation promotion group
-
19
2019.06
TOT BIOPHARM and Jun shi biological agreement
-
01
2019.02
Project of TOT was awarded as "excellent case" of corporate social responsibility construction in suzhou industrial park
-
20
2018.12
Dr. Liu jun of TOT BIOPHARM was awarded "high-level talents of jinji lake talent program"
-
11
2018.11
Good news! TOT BIOPHARM was selected as "2018 annual unicorn breeding enterprise of suzhou".
-
09
2018.09
Chinese anti-cancer rehabilitation association suzhou backbone training course
-
27
2019.09
Be in the lead! TOT BIOPHARM will release ADC drug TAA013 clinical phase I data
-
20
2018.12
The first subjects in the phase I study of TOT BIOPHARM antibody-coupled drug were enrolled for administration
-
14
2018.09
TAA013, an antibody coupled drug of TOT BIOPHARM has been approved clinically
-
13
2018.09
Touching life - remember cancer star story reading club
-
08
2018.08
TOT completed the B round financing of 102 million us dollars.
-
25
2018.05
The production base of TOT BIOPHARM has been completed and put into operation.
-
18
2018.05
Good news!TOT BIOPHARM announced the results of phase I clinical trial of the biosimilar drug TAB008 bevacizumab
-
24
2018.04
The national drug evaluation center officially accepted the clinical application of TAA013, an antibody-coupled drug from TOT
-
09
2018.03
In 2017, Yi qi said the annual selection of the biological industry was announced
-
02
2018.02
Seven years accumulation,TOT BIOPHARM international departure | JPM
-
01
2017.12
2017 annual suzhou technology advanced service enterprise report
-
18
2017.07
The integration and development of private enterprises and taiwan-funded enterprises in suzhou achieved fruitful results
